Deutsche Märkte schließen in 3 Stunden 36 Minuten

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
122,41-1,68 (-1,35%)
Börsenschluss: 04:00PM EST
122,40 -0,01 (-0,01%)
Nachbörse: 07:00PM EST
Melden Sie sich an, um eine Nachricht zu posten.
  • j
    jim
    $SLS conversation
    For anyone who doesn't already know about this AML drug comp $jazz paid $1.5B for $cpxx - This is the real value of Gps, unlike todays short sold, manipulated price. Cpxx treats the same AML patients, same $200M in estimated revenue for patients in secondary remission. https://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
  • G
    G$
    $SLS conversation
    SlS gets bought for over a billion. $jazz would paid $1.5B for Cpxx when it released its p3 data.
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals ($JAZZ) was set to buy Celator ($CPXX), and early this morning, the two confirmed the $1.5 billion deal was to go ahead.

    Jazz Pharmaceuticals said it will acquire Celator for $30.25 per share in cash--making the deal worth a total of $1.5 billion. The Irish company will gain access to the Ewing, NJ-based company's lead experimental blood cancer drug Vyxeos (CPX-351), which just last week gained an FDA “breakthrough therapy” designation.

    The FDA’s designation--which speeds up its review of a new medicine--is for patients with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

    A recent Phase III trial met its primary endpoint by showing statistically significant improvement in overall survival; detailed data will be presented at ASCO next week.

    Its current data for the drug showed median overall survival for patients treated with Vyxeos was 9.56 months compared with 5.95 months--a 3.61-month improvement in favor of Celator’s treatment against a chemotherapy agent known as 7+3.
  • j
    jim
    $SLS conversation
    For anyone who doesn't already know about this AML drug comp $jazz paid $1.5B for $cpxx - This is the real value of Gps, unlike todays short sold, manipulated price. Cpxx treats the same AML patients, same $200M in estimated revenue for patients in secondary remission. https://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
  • j
    jim
    $SLS conversation
    $Jazz Bought this AML Drug for $1.5B when it Published its Phase 3 Data. Same Exact Patients as Gps Same Exact Revenue Projections as GPS for AML Cr2. This was the last Fda approved drug in this setting...
    Celatorhttps://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
  • j
    jamboree
    $SLS conversation
    This is why the 1,000% gains in 5 or so months are likely - $jazz bought CPXX for $1.5B and its only drug extended survival to 9 months with Severe SA's. GPs extended OS to 21 months with No SA's. Same REV
    Celator previously projected sales between $200 million and $270 million in the U.S. and European markets; although sales could top out between $690 million and $780 million if Vyxeos is approved to treat AML patient populations outside of the subset used in the Phase-3 study.

    The only reason paying a 73% premium for CPXX stock isn’t a boneheaded move for JAZZ stock owners is because it ostensibly solves a serious problem: Jazz Pharma’s star drug, Xyrem, which hauled in $955 million last year (over 70% of overall sales), is losing patent protection in 2019.

    That means a flood of lower-cost generic competition, and a massive hit to the Jazz cash cow. Something had to be done. And although JAZZ stock owners may be pinching themselves over the fact that CPXX stock is fetching $30 a share despite trading well below $2/share prior to its Phase-3 trial results, Celator truly does have something special on its hands.

    Bottom Line on the CPXX and JAZZ Deal
    Vyxeos appears to be a virtual lock for FDA approval, and after publishing its trial data in March, biotech guru Adam Feuerstein applauded the company as “the first in 40 years to develop a drug which improves upon the standard of care for elderly patients with high-risk acute myeloid leukemia.”
  • E
    Ez$
    $SLS conversation
    $jazz Buyout / direct market comp -hardly anyone thought much of Celator Pharmaceuticals. The cancer drug developer’s stock was trading for less than $2 a share on thin volumes.

    Today, the Ewing, N.J.-based maker of a drug for acute myeloid leukemia said it’s getting acquired by Dublin, Ireland-based Jazz Pharmaceuticals for $30.25 a share—a total value of $1.5 billion. The price represents a 72% premium over Celator’s previous market close on Friday. Some positive clinical trial results from a cancer trial drove its value all the way from $1.68 a share in March 14 to $30.25 on May 31.

    Celator has staked its business on technology for combining old chemotherapy drugs in new ways, via liposomal nanoparticles that are supposed to improve targeted delivery of the chemo to tumors. Celator’s lead drug candidate is a combination of cytarabine and daunorubicin (Vyxeos, formerly known as CPX-351). The company said in March that patients on its drug with high-risk secondary acute myeloid leukemia lived a median time of 9.56 months—meaning half lived longer, and half didn’t live that long. That median survival time compared with 5.95 months for patients who were randomly assigned to get the standard treatment with cytarabine and daunorubicin. Side effects of the chemotherapy appeared to be similar between the two groups, researchers said.
  • R
    Real Immuno Investor 10
    $SLS conversation
    What do you think the share price will be when the data becomes imminent?
    What will it be when the data is released? $80, 120 per share or more is easily doable, $jazz bough $CPXX for 1.5b ($90per SLS Share) when it Published its p3 results.
    -
    It also helps SLS is in the best financial condition ever in co history, 2 years of cash, $200m in license rev funding operations, and 4 more additional Catalysts over the next 75 days, SLS could easily double or quintuple in this time.

    Fda Approval is a virtual certainty. Listen to the Webcast GPs symposium on the sellas site. At the 1:05 mark dr Levy lays it out. Gps is a virtual lock. GPs extended survival in every single previous trial including both Gps AML Phase 2 trials at MSK and the Moffit center.
  • j
    jim
    $SLS conversation
    $100 Per Share is coming
    $Jazz bought $cpxx for $1.5B right When it published its P3 AML data, it had rev projections of $200M just like GPS initial cr2 target. Yet sls trades for .13b ? stock Price up 1,500% in a matter of days.
    The Gps P3 writing is on the wall - 10 to 25x opportunity
    https://www.fool.com/investing/2016/06/27/why-celator-pharmaceuticals-is-up-1610-in-2016.aspx
    That's no typo. This biotech has a cancer candidate that Jazz investors will be watching like a hawk.
    That's no typo. This biotech has a cancer candidate that Jazz investors will be watching like a hawk.
    www.fool.com
  • E
    Ez$
    $SLS conversation
    100x times more Short lying than usual AND Every single Short liar on this board now knows they are in over sold territory. Massive Squeeze coming to $SLS. LOWEST OF LOWLIFE LYING ABOUT A BABY BIO WORKING ON CANCER CURES $AMC TYPE SQUEEZE COMING $GME TYPE SQUEEZE COMING $GLSI 2,600% GAINS IN ONE DAY SLS about to report news just like GLSI DID... IMMINENT TRIAL RESULTS. Jason McCarty Is Calling for a 300% Gain HERE $SAVA
    -- In less than a year, 6-9 months -->$SLS will Report phase 3 data to FDA that is worth 25X todays share price, we can only win.
    The last drug treating these patients got bought by $Jazz for $1.5B SLS Now trades for .09B.
    Ez money.
    The Most Obvious and Desperate Short Squeeze Set Up in the Whole Market with Multiple Catalysts IMMINENT.

    Buy SOME SLS and squeeze these short squealing rats.
  • C
    Cured
    $SLS conversation
    $SLS $JAZZ bought cpxx for $1.5B when it published its Phase 3 AML data, They Paid $1.5B based on expected Rev of $200M per year. - Cantor Fitz Estimates SlS Revenue of $200M - $600M
    - Gps Phase 3 Results in 2 or 3 quarters and it only trades for 1/ 10 one tenth to 1/3oth of that...
  • j
    jim
    $SLS conversation
    Spidey senses $SLS About to Go GREEN - $sls accumulation complete about to run all the way up to the FDA approval 1,000% Incoming - $jazz bought the last aML approved drug for $1.5B, SLS trades for .15b 1,000% Incoming Best Short Term Investment in the Whole Market
  • C
    Cured
    $SLS conversation
    $SLS $JAZZ bought cpxx for $1.5B when it published its Phase 3 AML data, They Paid $1.5B based on expected Rev of $200M per year. - Cantor Fitz Estimates SlS Revenue of $200M - $600M
    - Gps Phase 3 Results in 2 or 3 quarters and it only trades for 1/ 10 one tenth to 1/3oth of that...
  • j
    jim
    $SLS conversation
    Is this the last dip to get filled ? We will see.
    Facts are Shares will be much closer to $100 than $10 when the FDA P3 data comes in.
    Best Short term Investment in the whole Market. $Jazz bought the last AML FDA approved drug for $1.5B $Sls now trades for a paltry .14B.
  • j
    jim
    $SLS conversation
    Imagine this time last year you could load up on these at 1.83, this time next year SLS easily could be $183 - SLS has so few shares floating thats only $2.89b in Market cap. $jazz paid $1.5B for a company that just treated AML Cr2, the patients in the GPS PHASE 3 coming up for FDA approval. Gps is a lock based on dr. levy's remarks, GPS also treats CR1 patients, 5x the cr2 number. $180 something isn't farfetched by any means.
    It's what happens all the time in the drug development business.
  • C
    Cured
    $SLS conversation
    By now we all know $JAZZ paid $1.5B to buy $CPXX for its only drug, Vyxeos that treats AML Secondary patients a niche market for sure. The same niche Gps will be getting FDA approval for shortly - Same Exact Patients.
    $SlS has about 15.8m shares, forgetting all the cancers Gps treats, this one Patient setting is a direct hit comp.
    Very SIMPLE Math 15.8m SLS shares at $1.5B is a -$95- share price, lock some in while they’re cheap.
  • j
    jim
    $SLS conversation
    Imagine, this time last year you could load up on these at 1.83, by this time next year SLS easily could be $183 - SLS has so few shares floating thats only $2.89b in Market cap. $jazz paid $1.5B for a company that just treated AML Cr2, the patients in the GPS PHASE 3 coming up for FDA approval. Gps is a lock based on dr. levy's remarks, GPS also treats CR1 patients, 5x the cr2 number. $180 something isn't farfetched by any means.
    It's what happens all the time in the drug development business.
  • j
    jim
    $SLS conversation
    Just Imagine, at this time last year, you could buy these shares for $1.83, Next year you could easily be Selling for $183. That is only a $2.8B Market Cap - Low float baby bios Do Grow Up. $jazz paid $1.5B for the last Drug that treats AML Cr2, like the patients in the GPS P3 approaching FDA Approval. Gps also treats the CR1 patients, 5x the number in Cr2. Gps is undervalued. Listen to Dr Levy's remarks, The Director of Hematologic Research at Baylor essentially just said GPs Approval is a Lock. Lock and Load while the Market sells off. Ez$
  • j
    jim
    $SLS conversation
    DD $183 very possible by this time Next Year- or Sooner. GPS the PHASE 3 FDA REVIEW Sometime First half of 22'. $CPXX got bought by $JAZZ when its P3 DATA WAS PUBLISHED / Gps treats CR1 too 5x the size 5X
    https://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
    After holiday weekend rumors, Jazz confirms $1.5B buyout of tiny Celator
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal
  • C
    Cured
    $SLS conversation
    By now we all know $JAZZ paid $1.5B to buy $CPXX for its only drug, Vyxeos that treats AML Cr2 patients- a niche market for sure. The same niche Gps will be getting FDA approval for shortly - Same Exact Patients.
    $SlS has about 15.8m shares, forgetting all the cancers Gps treats, this one Patient setting is a direct hit comp.
    Very SIMPLE Math 15.8m SLS shares at $1.5B is a -$95- share price, lock some in while they’re cheap.
    CPXX was bought when they Published the Phase 3 data.
  • C
    Cured
    $SLS conversation
    1,000% to 2,500% Gains Incoming - Best Short Term Investment in the whole Market - Gps Phase 3 data First half of 22 -massive climb heading up to it - You will be grateful as #$%$ and bragging you bagged some in the Single Digits. $JAZZ bought the last AML cr2 drug for $1.5B and it was chemo that has serious Black Box warnings.
    Dr Levy Just explained Gps is a Virtual Lock for approval --
    Dr. Moshe Yair Levy, Director of Hematologic Malignancies at Baylor University Medical Center and member of the GPS REGAL Phase III Steering Committee, said this Aug 17 : "The preliminary data that we see looks fantastic, so whenever you have, 3-4x the expected survival...in a uniformly deadly disease like acute myelogenous leukemia, you certainly take notice...What we've seen so far is...nothing short of spectacular and hopefully that data can be maintained...We are talking 300-400% [preliminary improvement in OS, so] even if that gets whittled down, it's still a very meaningful difference."

    How many doctors would consider 50% improvement in overall survival to be clinically meaningful? Well, ASCO guidelines suggest 20% relative improvement in median OS, so I'm guessing a preponderance of doctors. Referring back to the symposium, when asked by Dr. Stergiou to talk about his confidence in the GPS data, Dr. Moshe Yair Levy, Director of Hematologic Malignancies at Baylor University Medical Center and member of the REGAL Phase III Steering Committee, said this:
    Ask yourself, what are the odds that REGAL data suddenly do a 180 to negate 300%? Nope.
    --
    Jennx6 Bullish 9/10/21 Great Post Had to REUP

    Cantor Fitz projects Revenue of $200M in 2023:

    In june the Ceo stated clearly FDA approval at Interim in First half of 2022 - now is the time to get loaded.

    From the Cantor Fitzgerald upgrade last week "With interim data and top-line data from the trial expected in H1 2022 |, respectively, the analysts expect the commercialization of the therapy in 2023, subject to positive trial results."

    "Considering a niche. segment of AML patients, the firm projects $200M of peak sales for GPS initially, before the drug is indicated for a broader set of AML patients as well as for additional indications in combination with other treatments..."

    Cantor has set an. $18.00 per share price target for SELLAS to imply a premium of 110%